xeljanz Drug Patent Profile

Which patents cover Xeljanz, and what generic alternatives are available?

Xeljanz is a drug marketed by Pfizer and Pf Prism Cv and is included in three NDAs. There are four patents protecting this drug and three Paragraph IV challenges.

This drug has seventy-five patent family members in fifty-two countries.

The generic ingredient in XELJANZ is tofacitinib citrate. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the tofacitinib citrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xeljanz

A generic version of xeljanz was approved as tofacitinib citrate by AJANTA PHARMA LTD on August 19^th, 2025.

Summary for xeljanz

International Patents:	75
US Patents:	1
Applicants:	2
NDAs:	3
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	30
Patent Applications:	998
Drug Prices:	Drug price information for xeljanz
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for xeljanz
What excipients (inactive ingredients) are in xeljanz?	xeljanz excipients list
DailyMed Link:	xeljanz at DailyMed

See drug prices for xeljanz

Recent Clinical Trials for xeljanz

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Takeda	Phase 4
Children's Hospital Los Angeles	Phase 2
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	Phase 4

See all xeljanz clinical trials

Pharmacology for xeljanz

Drug Class	Janus Kinase Inhibitor
Mechanism of Action	Janus Kinase Inhibitors

Paragraph IV (Patent) Challenges for XELJANZ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XELJANZ	Oral Solution	tofacitinib citrate	1 mg/mL	213082	1	2021-11-12
XELJANZ	Tablets	tofacitinib citrate	10 mg	203214	1	2019-07-24
XELJANZ	Tablets	tofacitinib citrate	5 mg	203214	3	2016-11-07

US Patents and Regulatory Information for xeljanz

xeljanz is protected by one US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	XELJANZ	tofacitinib citrate	SOLUTION;ORAL	213082-001	Sep 25, 2020		RX	Yes	Yes	RE41783*PED				Y
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-002	May 30, 2018		RX	Yes	Yes	RE41783*PED				Y
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-001	Nov 6, 2012		RX	Yes	No	RE41783*PED				Y
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-002	Dec 12, 2019		RX	Yes	Yes	10,639,309*PED				Y
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-001	Feb 23, 2016	AB	RX	Yes	No	RE41783*PED				Y
Pfizer	XELJANZ	tofacitinib citrate	SOLUTION;ORAL	213082-001	Sep 25, 2020		RX	Yes	Yes

Expired US Patents for xeljanz

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-001	Nov 6, 2012	6,956,041
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-001	Nov 6, 2012	7,301,023
Pfizer	XELJANZ	tofacitinib citrate	SOLUTION;ORAL	213082-001	Sep 25, 2020	6,956,041
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-002	May 30, 2018	7,301,023
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-002	May 30, 2018	7,842,699
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-001	Nov 6, 2012	7,842,699

International Patents for xeljanz

See the table below for patents covering xeljanz around the world.

Country	Patent Number	Title	Estimated Expiration
Guatemala	200000208	COMPUESTOS DE PIRROLO[2,3-D]PIRIMIDINA.
European Patent Office	1382339	Compositions contenant des dérivés de pyrrolo 2,3-d pyrimidine (Compositions containing pyrrolo 2,3-d pyrimidine derivatives)
South Africa	200307982	Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors.
World Intellectual Property Organization (WIPO)	02096909
Cyprus	1108850
Denmark	1451192

Supplementary Protection Certificates for xeljanz

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1666481	C201730033	Spain		PRODUCT NAME: TOFACITINIB Y SALES FARMACEUTICAMENTE ACEPTABLES DEL MISMO, INCLUYENDO LA SAL CITRATO; NATIONAL AUTHORISATION NUMBER: EU/1/17/1178; DATE OF AUTHORISATION: 20170322; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1178; DATE OF FIRST AUTHORISATION IN EEA: 20170322
1666481	CA 2017 00035	Denmark		PRODUCT NAME: TOFACITINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, HERUNDER CITRAT-SALTET; REG. NO/DATE: EU/1/17/1178/001-003 20170324
1666481	PA2017025	Lithuania		PRODUCT NAME: TOFACITINIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS PAVIDALE, ISKAITANT CITRATO DRUSKAAA; REGISTRATION NO/DATE: EU/1/17/1178 20170322
1666481	132017000095300	Italy		PRODUCT NAME: TOFACITINIB, OPZIONALMENTE NELLA FORMA DI UN SALE FARMACEUTICAMENTE ACCETTABILE, COMPRENDENTE IL SALE CITRATO(XELJANZ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1178/001-004, 20170324
1666481	CR 2017 00035	Denmark		PRODUCT NAME: TOFACITINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, HERUNDER CITRAT-SALTET; REG. NO/DATE: EU/1/17/1178/001-003 20170324
1666481	PA2017025,C1666481	Lithuania		PRODUCT NAME: TOFACITINIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS PAVIDALE, ISKAITANT CITRATO DRUSKAAA; REGISTRATION NO/DATE: EU/1/17/1178 20170322

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: XELJANZ

Last updated: July 27, 2025

---

Introduction

XELJANZ (tofacitinib) is a Janus kinase (JAK) inhibitor developed by Pfizer for the treatment of autoimmune diseases, primarily rheumatoid arthritis (RA). Since its initial approval, XELJANZ has emerged as a significant player within the biologics and targeted synthetic DMARD (Disease-Modifying Anti-Rheumatic Drug) markets. This analysis explores the evolving market landscape, competitive dynamics, regulatory environment, and financial performance influencing XELJANZ's trajectory.

---

Market Overview and Therapeutic Positioning

The global rheumatoid arthritis market was valued at approximately $24.3 billion in 2022 and is projected to reach $42.7 billion by 2030, growing at a CAGR of around 7.1% (source: Grand View Research). XELJANZ's role in this expanding space is characterized by its oral administration advantage over injectable biologics, broadening its appeal to patients seeking convenience and swift symptom relief.

XELJANZ’s indications have expanded beyond RA to include psoriatic arthritis (PsA), ulcerative colitis (UC), and ankylosing spondylitis, aligning with Pfizer’s strategic push into inflammatory and autoimmune diseases. In 2022, these indications contributed significantly to its revenue, reflecting its broad therapeutic applicability.

---

Market Dynamics

1. Competitive Landscape

XELJANZ faces intense competition from both traditional biologics and other targeted synthetic DMARDs. Notable competitors include:

• AbbVie’s Humira (adalimumab): The leading biologic for RA, with revenue exceeding $20 billion globally in 2022, though facing patent expiry and biosimilar entry.
• Eli Lilly’s Olumiant (baricitinib): A second-generation JAK inhibitor approved for RA, offering a direct competitive threat due to similar mechanism and oral administration.
• Gilead’s Jyseleca (filgotinib): Approved in select markets, representing emerging competition in JAK inhibition space.

The entry of biosimilars and generics into the biologics market compresses pricing and margins, positioning XELJANZ's niche of orally administered, small-molecule inhibitors as a strategic advantage.

2. Regulatory and Pricing Trends

Regulatory agencies globally are increasingly scrutinizing the safety profile of JAK inhibitors, particularly concerning thromboembolic events and malignancies. Post-marketing safety updates and black box warnings influence prescriber preferences and reimbursement policies.

Pricing pressures in major markets, especially in the U.S. and Europe, are driven by payer negotiations and the advent of biosimilars, affecting revenue sustainability. Nonetheless, Pfizer’s strong patent protections and ongoing trial data bolster XELJANZ's market positioning.

3. Technological Innovations and Pipeline

Advancements in personalized medicine and biomarker-guided therapy inform treatment selection, potentially expanding XELJANZ’s use cases. Pfizer’s ongoing clinical trials aim to reinforce efficacy and safety profiles, with potential label expansions into additional autoimmune conditions, broadening revenue streams.

---

Financial Trajectory and Revenue Analysis

1. Historical Performance

XELJANZ generated approximately $2.4 billion in revenue in 2022, representing roughly a 10% increase year-over-year, reflecting resilient demand amid competitive pressures. Key drivers include:

• Strong adoption in RA, especially among biologic-naïve patients.
• Growing indications in UC, which contributed approximately 25% of total sales.
• Geographic expansion, notably in emerging markets, where oral administration and cost advantages appeal due to healthcare access constraints.

2. Revenue Drivers and Future Potential

Projected growth relies heavily on several factors:

• Indication expansion: Approval for UC in additional jurisdictions, such as Japan and Europe, could add upward revenue momentum.
• Market penetration in underserved populations: Increasing adoption in developing markets, facilitated by affordability initiatives.
• Price management strategies: Pfizer’s negotiations with payers and strategies to mitigate biosimilar impact are pivotal.

3. Challenges to Financial Growth

Key hurdles include safety concerns leading to prescription hesitancy, competitive erosion from newer agents, and regulatory modifications necessitating extensive post-marketing studies. The expiration of patents in 2024-2025 in key markets could introduce biosimilar competition, impacting pricing power.

---

Strategic Outlook and Investment Considerations

Pfizer’s strategic focus on diversifying its autoimmune portfolio and investing in innovative formulations and delivery methods underpin XELJANZ’s future trajectory. Additionally, leveraging real-world evidence for safety and efficacy reinforces market confidence.

Investors and stakeholders should monitor:

• Pipeline catalysts: Trials for additional indications and improved formulations.
• Regulatory developments: Safety labeling updates and approval timelines.
• Market share dynamics: Competitive movements and biosimilar entries.

Overall, XELJANZ remains a financially robust product with moderate growth prospects, contingent on safety, market expansion, and competitive strategies.

---

Key Market Trends Influencing Outlook

Trend	Impact on XELJANZ
Growing prevalence of autoimmune diseases	Expands total addressable market
Increased safety monitoring	Could lead to label modifications
Biosimilar entry	Pressures pricing, margins
Expansion into new indications	Opportunities for growth
Digital health integration	Enhances patient adherence and real-world data collection

---

Conclusion

XELJANZ’s market position underscores a complex interplay of therapeutic efficacy, safety profile, competitive pressures, and regulatory landscapes. While facing challenges from biosimilars and safety concerns, Pfizer’s strategic initiatives and pipeline developments position XELJANZ for continued relevance, particularly in expanding indications and geographic markets. Its financial trajectory is cautiously optimistic, guided by innovative clinical evidence, market expansion, and the evolving autoimmune treatment paradigm.

---

Key Takeaways

• XELJANZ’s oral administration offers a competitive edge amid biologic dominance, supporting steady revenue streams.
• Market growth hinges on successful indication expansion, safety profile management, and geographic penetration, especially in emerging markets.
• Biosimilar competition and regulatory scrutiny pose challenges, necessitating strategic pricing and safety communication.
• Ongoing clinical trials and pipeline developments are critical to future revenue growth and market differentiation.
• Stakeholders should maintain vigilance on patent expirations, market entry of competitors, and evolving regulatory landscapes to optimize investment outcomes.

---

FAQs

1. What distinguishes XELJANZ from other JAK inhibitors?
XELJANZ is orally administered, which offers convenience over injectable biologics and certain other JAK inhibitors. It has broad FDA and EMA approval for RA, PsA, UC, and other autoimmune conditions, positioning it as a versatile option.

2. How have safety concerns impacted XELJANZ's market performance?
Safety warnings related to thromboembolic risks and malignancies have slightly tempered prescribing trends, prompting post-marketing safety updates. Nonetheless, its efficacy continues to sustain demand within the approved indications.

3. What is the outlook for XELJANZ with the entry of biosimilars?
While biosimilar competition, especially in biologic markets, often pressures prices, XELJANZ benefits from its small-molecule status, making it less susceptible to biosimilar erosion. However, generic competition in certain markets remains a possible threat.

4. Which emerging indications could significantly impact XELJANZ's revenue?
Expansion into ulcerative colitis in additional markets and new autoimmune conditions, such as ankylosing spondylitis, could notably elevate sales if regulatory approvals are secured.

5. How does Pfizer plan to sustain XELJANZ's growth amidst competitive challenges?
Pfizer invests in pipeline diversification, safety profile reinforcement, and geographical expansion, notably in emerging markets, to maintain XELJANZ's relevance and revenue contribution.

---

Sources

[1] Grand View Research. "Rheumatoid Arthritis Market Size, Share & Trends Analysis." 2022.
[2] Pfizer Annual Reports, 2022.
[3] EMA & FDA Regulatory Updates on JAK Inhibitors, 2022-2023.
[4] IQVIA Market Data, 2022.
[5] GSK, Pfizer, and other pharma company pipeline disclosures, 2022.